ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026
De novo belatacept-based immunosuppression is not associated with increased risk of invasive fungal infection in kidney transplant recipients.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The risk of invasive fungal infection (IFI) in kidney transplant recipients (KTRs) receiving de novo belatacept-based immunosuppression remains incompletely understood. We conducted a single-center retrospective cohort study of adult KTRs receiving de novo belatacept- or tacrolimus-based immunosuppression between 2016 and 2025. Cumulative incidence of IFI was estimated using competing-risks methods with death as a competing event and compared using Gray's test. Associations between immunosuppression and IFI risk were evaluated using a cause-specific Cox model, with thymoglobulin and high-dose steroids modeled as time-dependent covariates. A prespecified propensity score-matched cohort was analyzed to address selection bias. Associations between IFI and mortality were assessed using time-dependent Cox proportional hazards models. Among 2729 KTRs, 1875 (68.7%) received belatacept and 854 (31.3%) tacrolimus. The 1-year cumulative incidence of IFI was 1.4% in belatacept-treated patients vs 1.8% in tacrolimus-treated patients (P = .47). Belatacept compared with tacrolimus was not associated with IFI (hazard ratio, 0.87; 95% confidence interval, 0.54-1.39). IFI was associated with mortality (hazard ratio, 5.03; 95% confidence interval, 3.12-8.09). Similar results were observed in the propensity score-matched cohort. De novo belatacept-based immunosuppression does not confer increased risk of IFI, and routine antifungal prophylaxis may not be necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.